Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1413000 | 0.83 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL11275622 | 0.83 | GAA (0.39) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL9865139 | 0.81 | GAA (0.46) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL7713280 | 0.80 | GAA (0.55) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL842414 | 0.78 | — | — | |
| SCHEMBL11319534 | 0.77 | ALDH1A1 (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL10679239 | 0.77 | GAA (0.61) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL2539602 | 0.77 | GAA (0.42) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL13638352 | 0.77 | GAA (0.42) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL184487 | 0.77 | HDAC3 (0.46) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007132475-A1 | SELECTIVE TR-BETA 1 AGONIST | CADILA HEALTHCARE LIMITED (IN) | 2007-11-22 | — | — | WO | claimed |
| CN-118440093-A | Asymmetric unilateral compound, oligomeric donor and solar cell device | 国家纳米科学中心 | 2024-08-06 | — | — | CN | disclosed |
| WO-2023283369-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC (US) | 2023-01-12 | — | — | WO | disclosed |
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| CN-110914254-A | Azole-substituted pyridine compound | 大正制药株式会社 | 2020-03-24 | — | — | CN | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-21 | — | — | US | disclosed |
| EP-2738163-B1 | AMIDINE COMPOUND OR SALT THEREOF | TAISHO PHARMACEUTICAL CO LTD (JP) | 2016-01-20 | — | — | EP | disclosed |
| WO-2001095910-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| US-5538970-A | Treatment of cancer with imidazo-1,2-pyridazin compounds | GLAXO WELLCOME INC. (US) | 1996-07-23 | — | — | US | disclosed |
| US-5447956-A | Anticarcinogenic agents | BURROUGHS WELLCOME CO. (US) | 1995-09-05 | — | — | US | disclosed |
| US-5380759-A | Methyl N-[6-(3,4,5-trimethoxybenzloxy)imidazo[1,2-b]pyridazin-2-zyl]carbamate used to treat leukemia | BURROUGHS WELLCOME CO. (US) | 1995-01-10 | — | — | US | disclosed |
| US-5371219-A | Antitumor agents | BURROUGHS WELLCOME CO. (US) | 1994-12-06 | — | — | US | disclosed |
| CN-1085901-A | Preparation contains the method for the antineoplastic pharmaceutical compositions of Imidazopyridazine derivative | WELLCOME FOUND (GB) | 1994-04-27 | — | — | CN | disclosed |
| WO-1992013837-A1 | A PROCESS FOR THE PREPARATION OF 3-ACYLAMINO-4-CARBAMOYLOXYMETHYL-2-AZETIDINONE-1-SULPHONIC ACIDS AND INTERMEDIATES FOR THE PREPARATION THEREOF | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 1992-08-20 | — | — | WO | disclosed |
| US-5091531-A | Antitumor agents | BURROUGHS WELLCOME CO. (US) | 1992-02-25 | — | — | US | disclosed |
| CN-1031532-A | HETEROCYCLIC COMPOUNDS | WELLCOME FOUND (GB) | 1989-03-08 | — | — | CN | disclosed |
| EP-0305093-A1 | Imidazo(1,2-b)pyridazine derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | GAA 3192/4885MGAM 879/4885SI 603/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | GAA 3192/4885MGAM 879/4885SI 603/4885 |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | GAA 4027/4885MGAM 3963/4885SI 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.